Closing Thoughts On US FDA Advisory Committee Reforms

 
• By Michael McCaughan

One speaker at the US FDA’s day-long “listening session” on advisory committee reform captured an important truth: the problem is not necessarily how committees are run, it is that there are no alternatives for public input into agency decisions.

Window into empty store
The FDA may need a larger window into its decision-making. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers